This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2018-2021.
Location History:
- Gifu, JP (2018)
- Kakamigahara, JP (2021)
Company Filing History:
Years Active: 2018-2021
Title: Kentaro Nagane: Innovator in Pharmaceutical Chemistry
Introduction
Kentaro Nagane is a prominent inventor based in Gifu, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in developing methods to enhance drug formulations. With a total of 2 patents, his work focuses on improving the efficacy and palatability of pharmaceutical compounds.
Latest Patents
Kentaro Nagane's latest patents include a method for suppressing the bitterness of quinoline derivatives. This invention provides a novel approach to enhance the taste profile of these compounds, making them more acceptable for patients. Another significant patent is a pharmaceutical composition of fused aminodihydrothiazine derivatives. This invention comprises a specific compound and its pharmaceutically acceptable salts, aimed at improving therapeutic outcomes.
Career Highlights
Kentaro Nagane is currently associated with Eisai R&D Management Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing drug formulations that cater to patient needs. His dedication to research and development has positioned him as a key figure in his field.
Collaborations
Kentaro has collaborated with notable colleagues, including Yosuke Ueki and Shusuke Sano. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in pharmaceutical chemistry.
Conclusion
Kentaro Nagane's contributions to pharmaceutical chemistry through his patents and collaborations highlight his commitment to improving drug formulations. His innovative methods are paving the way for more effective and patient-friendly medications.
